Labiana Health (XMAD:LAB) Accounts Receivable : €8.78 Mil (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Labiana Health's accounts receivables for the quarter that ended in Dec. 2022 was €8.78 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Labiana Health's Days Sales Outstanding for the quarter that ended in Dec. 2022 was 55.65.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Labiana Health's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was €-5.22.

Labiana Health Accounts Receivable Historical Data

The historical data trend for Labiana Health's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Accounts Receivable Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Accounts Receivable

10.47

7.93

8.78

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Accounts Receivable	10.47	7.93	11.78	8.78

Labiana Health Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Labiana Health Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Labiana Health's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.778	/	28.787	*	91
=	55.65

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Labiana Health's accounts receivable are only considered to be worth 75% of book value:

Labiana Health's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.544	+	0.75 * 8.778	+	0.5 * 13.833	-	53.873
-	0	-	-0.128)	/	7.22126
=	-5.22

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Labiana Health Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Labiana Health's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Accounts Receivable

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.